Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px
Document › Details

Addex Therapeutics S.A.. (2/7/18). "Press Release: Addex Appoints Jean-Philippe Rocher as Co-Head of Discovery and Member of the Executive Management". Geneva.

Organisations Organisation Addex Therapeutics S.A. (SIX: ADXN)
  Group Addex (Group)
  Organisation 2 Pierre Fabre S.A.
  Group Pierre Fabre (Group)
Products Product dipraglurant (ADX48621)
  Product 2 ADX71149 (Addex)
Persons Person Rocher, Jean-Philippe (Addex 201802– Co-Head Disovery before Pierre Fabre + Addex + Devgen + GSK Japan + Batelle)
  Person 2 Lütjens, Robert (Addex 201802 Head of Discovery)
     


Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today the appointment of Jean-Philippe Rocher, PhD, as Co-Head of Discovery and Member of the Executive Management. Dr. Rocher is a medicinal chemistry and drug discovery expert with more than 25 years industry experience, who previously built Addex’ small molecule allosteric modulator chemistry platform. Together with Robert Lütjens, Addex’s current Head of Discovery, he will oversee the preclinical portfolio of proprietary allosteric modulator programs and lead the chemistry components of our funded research programs on GABAB PAM with Indivior PLC and TrkB PAM with the Michael J. Fox Foundation for Parkinson’s Research.

“Putting back together the successful chemistry and biology partnership of Jean-Philippe Rocher and Robert Lütjens, which built the Addex allosteric modulator discovery platform and delivered our proprietary pipeline is a significant achievement,” commented Tim Dyer, CEO of Addex. “The team will initially focus on delivering on our funded research programs which are being conducted in collaboration with Indivior PLC and The Michael J. Fox Foundation for Parkinson’s Research.”

“I’m delighted to rejoin Addex and have the opportunity to continue the work that Robert Lütjens and I started in 2002”, added Jean-Philippe Rocher. “Allosteric modulation is an exciting field which holds huge potential to transform the treatment of CNS disorders. I am looking forward to deploying my expertise and experience back at Addex.”

Dr. Rocher returns to Addex from his current position as CNS Program Director at Pierre Fabre. Joining Addex at its inception in 2002, Dr. Rocher established the company’s chemistry capabilities and helped build its small molecule allosteric modulator chemistry platform and pipeline. He played a pivotal role in the success of both internal and partnered programs, including the discovery of dipraglurant and ADX71149, both of which progressed into phase II clinical development. Under the leadership of Dr Rocher, Addex team discovered ADX71441, which was recently licensed to Indivior PLC. Prior to joining Addex, Dr. Rocher was director of chemistry at Devgen NV (Gent, Belgium), senior research scientist for GlaxoSmithKline KK (Tsukuba, Japan), scientific project leader in CNS at Mitsubishi Tanabe (Yokohama, Japan) and Head of Drug Discovery Unit for Battelle (Geneva, Switzerland). He started his career as a research scientist in the dermatology research centre of Galderma (Sophia-Antipolis, France) following a PhD in medicinal chemistry and Pharm D at the Faculty of Pharmacy of Lyon (France).He is a co-author of more than 35 research publications and patents.


About Addex Therapeutics

Addex Therapeutics (www.addextherapeutics.com) is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform. Addex's lead drug candidate, dipraglurant (mGluR5 negative allosteric modulator or NAM) has successfully completed a Phase 2a POC in Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID with support from the Michael J. Fox Foundation for Parkinson's Research (MJFF). In parallel, dipraglurant's therapeutic use in dystonia is being investigated with support from the Dystonia Medical Research Foundation (DMRF). Addex's second clinical program, ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals, Inc for epilepsy. In addition, ADX71441 (GABAB receptor PAM) program was awarded a $5.3 million grant by the US National Institute on Drug Abuse (NIDA, a division of National Institutes of Health (NIH)) to support human studies in cocaine addiction and has been licensed to Indivior. Discovery programs include mGluR4PAM, mGluR7NAM, TrkBPAM and mGluR3NAM & PAM that are being advanced with the support of the MJFF and Swiss Commission for Innovation and Technology (CTI).


Press Contacts:

Tim Dyer Mike Sinclair
Chief Executive Officer Partner, Halsin Partners
Telephone: +41 22 884 15 55 +44 (0) 207 318 2955
Email: PR@addextherapeutics.com msinclair@halsin.com


Disclaimer / Forward-looking statements:

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Addex Therapeutics Ltd. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

   
Record changed: 2018-02-16

Advertisement

Picture EBD Group Biotech Showcase 2019 San Francisco BTS January 600x60px

More documents for Addex (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2019 Vienna Austria March 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Bio-Europe Spring 2019 Vienna Austria March 120x180px Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 120x180px